Navigation Links
Reportlinker Adds World Anti-Obesity Drug Market 2011-2021
Date:4/5/2011

NEW YORK, April 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Anti-Obesity Drug Market 2011-2021

http://www.reportlinker.com/p0470102/World-Anti-Obesity-Drug-Market-2011-2021.html

That will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level. 

We provide original research, data and opinions to benefit your work. By ordering now, you can stay ahead. We aim to save you time and benefit your decisions. 

How will the regulatory and marketing difficulties facing anti-obesity drugs affect companies and their revenues? In our report you will see prospects for obesity drug research, development, launches and marketing from 2011 onwards. 

We predict the overall world market and leading national markets. The increasing prevalence of obesity has created pharma market opportunities in many countries. 

Where will the best revenue prospects in obesity treatment lie from 2011 to 2021? Our study provides the answers you need for that pharma market.

Although sales have been modest so far, weight-loss drugs can gain acceptance from more prescribers, patients and payers. The prescription drug market for obesity can grow, despite setbacks at present, our study shows. You will see how. 

Anti-obesity drugs with improved clinical effectiveness, safety and ease of use can gain therapeutic and commercial success, our report explains. We show R&D progress there.

You will see strengths, weaknesses and revenue prospects of the anti-obesity drug market from 2009 to 2021. We show what companies are doing, and how competition is shaping up in that challenging environment. 

In our report you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.

Analysis and expert opinion to help your work - so you won't be left behind

Our new report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 78 tables and charts and two interviews (shown in the accompanying lists).

World Anti-Obesity Drug Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive hard data for the anti-obesity drug industry and market - especially our revenue forecasts to 2021

• You will discover revenues for the overall market and its main products from 2009 to 2021 - seeing where commercial growth will occur

• You will find revenue forecasts for leading products from 2011 to 2021, with discussions of market potential and competition

• You will find revenue forecasts for leading national markets from 2011 to 2021 (US, UK, Germany, France, Spain, Italy, Russia and India)

• You will learn how the anti-obesity drug industry can change and adapt from 2011 to 2021

• You will assess leading companies in obesity treatments, discovering their activities and outlook

• You will see what will stimulate and restrain the industry and market from 2011 onwards

• You will identify R&D pipeline advances and up-and-coming products

• You will investigate commercial requirements - with therapeutic needs and market opportunities discussed

• You will view expert opinion from our survey, including full interview transcripts

• You will find out where the industry and market are heading - technology, competition and revenues.

That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends. We give you market predictions found only in our work. Our independent analysis can help you stay ahead of your competitors.

You can order our report, receiving the market information you need 

Our report can benefit everybody interested in anti-obesity drug development, production, marketing and sales. You will find answers and predictions you need. Please order our report now, making sure you don't miss out. 

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what license is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 The Anti-Obesity Drug Market Has Potential to Increase its Revenues

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to the Anti-Obesity Drug Market

2.1 What is Obesity? 

2.1.1 Obesity as a Chronic Disorder

2.1.2 Obesity in Children 

2.2 Factors Leading to Obesity

2.2.1 Genetic Factors 

2.2.2 Psychological Factors

2.2.3 Environmental, Behavioural and Social Factors

2.2.4 Drug Factors

2.2.5 Mental and Physical Disability Factors

2.2.6 Other Factors

2.2.7 Antecedent Illnesses and Treatments

2.3 Measurement of Obesity

2.3.1 How is Obesity Measured? 

2.3.2 Weight-for-Height Tables

2.3.3 Waist Circumference

2.3.4 Body Mass Index (BMI) 

2.4 Obesity Has High Socio-Economic Costs

2.4.1 Consequences of Obesity: Co-Morbidities Linked to Obesity

2.5 Obesity is a Rising Challenge in Many Countries

2.5.1 Obesity in Established Markets

2.5.2 Current Burden of Obesity in Emerging Markets

2.6 Current Treatments for Obesity

2.6.1 Lifestyle and Dietary Changes

2.6.2 Unapproved Drugs in the Market

2.6.3 Alternative Therapies

2.6.4 Use of Drugs to Treat Obesity

2.6.5 Surgical Options

2.7 Anti-Obesity Drugs: Mechanisms of Action

2.7.1 Lipase Inhibitors

2.7.2 Anorectic Drugs 

2.7.3 Off-Label Use of Drugs in Obesity Treatment

2.7.4 Need for Developments and Innovation in the Treatment of Obesity

2.7.5 Unmet Needs and Market Potential

3. The World Anti-Obesity Treatments Market, 2011-2021

3.1 Anti-Obesity Drug Sales from 2009 Onwards: Market Overview

3.2 Leading Companies and their Products

3.3 Current Challenges with Anti-Obesity Drugs

3.3.1 Difficulties with Xenical, Alli and Reductil

3.3.2 Challenges with Acomplia 

3.3.3 Challenges with Phentermine

3.4 Overall World Anti-Obesity Market Forecast, 2011-2021

3.4.1 Anti-Obesity Treatments Market Growth, 2011-2021

4. Individual Anti-Obesity Drug Forecasts by Therapeutic Class, 2011-2021

4.1 Lipase Inhibitors

4.1.1 Xenical World Market Forecast 2011-2021 

4.1.2 Can Xenical Remain in the Market? 

4.1.3 Xenical Sales Down Through Generic Competition

4.1.4 Can Pipeline Drugs Push Xenical out of the Market?

4.1.5 Alli World Market Forecast 2011-2021

4.1.6 Alli a Form of Orlistat: First OTC Variation by GSK

4.1.7 Can Alli Resist Generic Competition? 

4.1.8 Alli: Additional Health Benefits?

4.2 Anorectic Drugs

4.2.1 Reductil/Meridia Forecast 2011-2021 

4.2.2 EU Decision on Reductil (Early 2010) 

4.2.3 US Decision on Reductil (Late 2010) 

4.2.4 Reductil Out of the Market

4.2.5 Reductil's Absence Creating a Hole in the Market

4.2.6 World Dinintel Market Forecast 2011-2021

4.3 Phentermine

4.3.1 World Duromine Market Forecast 2011-2021

4.3.2 Duromine Sales During the Forecast Period

4.4 Other Anti-Obesity Drugs: World Market Forecast 2011-2021

4.4.1 Generic Competitors

4.4.2 New Drug: Contrave (Orexigen) 

4.4.3 New Drug: Lorcaserin (Arena) 

4.4.4 New Drug: Qnexa (Vivus) 

4.4.5 New Drug: Liraglutide (Novo Nordisk) 

4.4.6 New Drug: Empatic/Excalia (Orexigen) 

4.5 Market Summary

4.5.1 New Drugs Will Refresh the Obesity Market

4.5.2 Market Opportunities Through Innovation

4.5.3 The Challenges with Anorectic Drugs

4.5.4 The Challenges with Lipase Inhibitors

4.5.5 The Future of Anti-Obesity Treatments

5. Drivers and Restraints in the World Anti-Obesity Treatments Market, 2011-2021

5.1 Strengths

5.1.1 Long-Term Therapy with Anti-Obesity Drugs 

5.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs

5.1.3 Growing Demand for New Drugs in this Market

5.1.4 Off-Label Potential in Some Markets

5.1.5 Strong Development Pipeline

5.2 Weaknesses

5.2.1 Limited Efficacy Observed in Prominent Drugs

5.2.2 Undesirable Side-Effects

5.2.3 Increased Competition from New Drugs and Generic Substitutes

5.2.4 Strict Regulatory Hurdles: Companies Pay the Price

5.2.5 Pharmacotherapy Not Likely to Become the First Line of Treatment

5.3 Opportunities

5.3.1 Rising Prevalence of Obesity Gives a Large Potential Market for Drugs

5.3.2 Increasing Potential for Success in Emerging Economies: India and China

5.3.3 Medical and Cosmetic Use of Anti-Obesity Drugs

5.3.4 High Governmental Awareness of the Obesity Problem Stimulates the Market

5.3.5 Pipeline Drugs Can Eventually Stimulate the Market

5.3.6 Diet and Exercise May be the Mainstay Treatment, but this Approach to Weight Management is Not Always Effective

5.3.7 Potential Shift from Rx (Prescription Only) to OTC (Over-the-Counter) Products

5.4 Threats

5.4.1 Lack of Reimbursement May Continue to be a Limiting Factor

5.4.2 Threats from Other Treatment Forms and Alternative Medicine

5.4.3 Regulatory Threats: Drug Recalls Decrease Confidence in Treatments, Harming the Overall Market

5.4.4 Shift to Healthier Lifestyles and Awareness Programmes Threaten the Anti-Obesity Drug Market?

5.4.5 Long-Term Safety Issues Continue to Inhibit Market Growth

5.4.6 Opinion of Prescribers, the Media and the Public Affects Product Success and the Success of the Overall Market

5.5 Summary of Chapter

6. R&D Pipeline for Anti-Obesity Treatments

6.1 Treatments Currently in Phase III

6.1.1 Contrave (Orexigen): FDA Approves Contrave

6.1.2 Cetilistat (Alizyme/Takeda) 

6.1.3 Liraglutide (Novo Nordisk) 

6.1.4 Canagliflozin (Johnson & Johnson) 

6.2 Treatments Currently in Phase II

6.2.1 Empatic/Excalia (Orexigen) 

6.2.2 Obinepitide (7TM Pharma) 

6.2.3 Davalintide (Amylin/Takeda) 

6.2.4 BMS 830216 (Bristol-Myers Squibb) 

6.2.5 Velneperit (Shionogi) 

6.2.6 Sodium Tungstate (Bayer/Barcelona University) 

6.2.7 Serglifozin Etabonate (GlaxoSmithKline/Kissei) 

6.2.8 Pramlintide and Metreleptin (Amylin) 

6.2.9 Hoodia Gordonii Extract (Phytopharm/Council for Scientific and Industrial Research) 

6.2.10 MTP Inhibitor (Johnson & Johnson) 

6.2.11 TM 30339 (7TM Pharma) 

6.2.12 KRP 204 (Kyorin) 

6.3 Treatments Currently in Phase I

6.3.1 Trodusquemine (Genaera) 

6.3.2 THCV (GW Pharmaceuticals) 

6.3.3 Oral PYY3-36 (Emisphere) 

6.3.4 AZD 4017 (AstraZeneca) 

6.3.5 AZD 6714 (AstraZeneca) 

6.3.6 AZD 1656 (AstraZeneca) 

6.3.7 NGD 4715 (Neurogen) 

6.3.8 OAP 189 (Pfizer) 

6.3.9 PF 4325667 (Pfizer) 

6.3.10 SRT 2104 (Sirtris/GlaxoSmithKline) 

6.3.11 ZYO 1 (Zydus Calida) 

6.3.12 BVT 74316 (Biovitrum) 

6.3.13 CP 404 (Compellis/Louisiana State University) 

6.3.14 TTP 435 (TransTech) 

6.3.15 PRX 07034 (Epix) 

6.3.16 PSN 602 (OSI Pharmaceuticals) 

6.3.17 TKS 1225 (Wyeth/Pfizer) 

6.4 Promising Pipeline Possibilities

6.4.1 Melanotan

6.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure

6.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption

6.4.4 Anti-Obesity Vaccine in the Pipeline

6.4.5 Vitamin B12 Injections

7. Anti-Obesity Drugs: Leading National Markets 2011-2021

7.1 The Overall Market for Anti-Obesity Drug Treatments

7.2 Drug Development Will Drive the Market

7.3 The US Anti-Obesity Treatments Market 2011-2021

7.3.1 Patent Expiries, FDA Warnings and New Drug Releases will Create a Turbulent Market

7.3.2 Market Growth in the Second Half of the Forecast Period

7.4 UK Anti-Obesity Market Forecast 2011-2021

7.4.1 Lagging Sales and Reductil's European Withdrawal 

7.4.2 Government Policy Will Benefit the Anti-Obesity Treatments Market in the UK

7.5 Spanish Anti-Obesity Market Forecast 2011-2021

7.5.1 New Drug Releases, Reductil's European Withdrawal and Patent Expiries Will Affect Short Term Growth

7.5.2 The Market Will Show Consistent Positive Growth from 2012 Onwards

7.6 German Anti-Obesity Market Forecast 2011-2021

7.7 French Anti-Obesity Market Forecast 2011-2021

7.7.1 Reimbursement Will Drive Steady Sales Growth Throughout the Forecast Period

7.8 Italian Anti-Obesity Treatments Market 2011-2021

7.9 Japanese Anti-Obesity Treatments Market 2011-2021

7.10 Russian Anti-Obesity Treatments Market 2011-2021

7.11 Top 5 EU Markets 2011-2021

7.12 Emerging Markets: Indian Anti-Obesity Treatments Market 2011-2021

7.13 Emerging Markets: Chinese Anti-Obesity Treatments Market 2011-2021 

7.14 Other Countries: Anti-Obesity Market Forecast 2011-2021

7.14.1 Revenues from the Other Countries Group Will Grow Significantly Throughout the Forecast Period

7.14.2 The Impact of Emerging Markets Will Contribute Heavily to Total Other Countries Market Growth

8. Expert Opinions from Our Survey

8.1 Interview with an Obesity Treatment Professional in Spain

8.1.1 Views on the Efficacy of Drugs for Obesity Treatment

8.1.2 Potential Obesity Treatments in the R&D Pipeline

8.1.3 Views on Major Anti-Obesity Drugs

8.1.4 Other Ways to Tackle the Obesity Problem: Diet, Exercise and Surgery

8.1.5 Insight into the Spanish Anti-Obesity Treatments Market

8.1.6 Drivers and Restraints in the Market

8.1.7 Future of the Anti-Obesity Treatments Market

8.2 Interview with Dr Marcio Mancini, Secretary of Endocrinology, Faculty of Medicine, University of Sao Paulo, Brazil

8.2.1 Views on the Anti-Obesity Treatments Market

8.2.2 R&D Pipeline for Anti-Obesity Treatments

8.2.3 Scope for Pharmacotherapy in the Treatment of Obesity

8.2.4 Drivers and Restraints in the Market 

9. Conclusions

9.1 Obesity is a Chronic Disorder with Serious Effects on Health

9.2 The Anti-Obesity Market will Expand from 2011 to 2021

9.3 Main Drivers and Restraints in the Anti-Obesity Drug Market

9.4 Geographical Overview of the Anti-Obesity Market

9.5 Outlook for the Future

List of Tables

Table 2.1 BMI Classification Bands

Table 2.2 Costs Incurred by the NHS (UK) for Anti-Obesity Treatments, 1999-2008 Table 2.3 Obesity Prevalence Among US Adults, 1991-2009

Table 3.1 Revenues ($m) for Leading Companies in the Anti-Obesity Drug Market, 2009

Table 3.2 Revenues ($m) for Leading Anti-Obesity Drug Treatments, 2009-2015

Table 3.3 Revenues ($m) for Leading Anti-Obesity Drug Treatments, 2015-2021

Table 3.4 Market Shares (%) of Leading Companies, 2009 and 2010

Table 3.5 World Anti-Obesity Drug Treatment Revenues ($m), 2009-2015

Table 3.6 World Anti-Obesity Drug Treatment Revenues ($m), 2015-2021 

Table 4.1 World Xenical Revenues ($m), 2009-2015

Table 4.2 World Xenical Revenues ($m), 2015-2021

Table 4.3 World Alli Revenues ($m), 2009-2015

Table 4.4 World Alli Revenues ($m), 2015-2021

Table 4.5 World Reductil Revenues ($m), 2009-2015

Table 4.6 World Reductil Revenues ($m), 2015-2021

Table 4.7 World Dinintel Revenues ($m), 2009-2015

Table 4.8 World Dinintel Revenues ($m), 2015-2021

Table 4.9 World Duromine Revenues ($m), 2009-2015

Table 4.10 World Duromine Revenues ($m), 2015-2021

Table 4.11 Other Anti-Obesity Drug Treatments: World Revenues ($m), 2009-2015

Table 4.12 Other Anti-Obesity Drug Treatments: World Revenues ($m), 2015-2021

Table 4.13 Anti-Obesity Drugs: World Market Shares (%) and Revenues ($m), 2015 and 2021

Table 5.1 SWOT Analysis of the Anti-Obesity Drug Treatments Market, 2011-2021

Table 6.1 Drugs Recently Rejected by the FDA

Table 6.2 R&D Pipeline for Anti-Obesity Drug Treatments, 2010

Table 7.1 Leading National Market Revenues ($m) for Anti-Obesity Drug Treatments, 2009-2015

Table 7.2 Leading National Market Revenues ($m) for Anti-Obesity Drug Treatments, 2015-2021

Table 7.3 US Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.4 US Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.5 UK Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.6 UK Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.7 Spanish Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.8 Spanish Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.9 German Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.10 German Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.11 French Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.12 French Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.13 Italian Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.14 Italian Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.15 Russian Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.16 Russian Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.17 Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2009-2015

Table 7.18 Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2015-2021

Table 7.19 Indian Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.20 Indian Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.21 Rest of the World: Anti-Obesity Drug Market Revenues ($m), 2009-2015

Table 7.22 Rest of the World: Anti-Obesity Drug Market Revenues ($m), 2015-2021

Table 7.23 World Market Shares (%) for Anti-Obesity Drug Treatments, 2009-2021

List of Figures

Figure 2.1 Obesity Prevalence among US Adults, 1991-2009

Figure 3.1 Revenues ($m) for Leading Companies in the Anti-Obesity Drug Treatments Market, 2009 

Figure 3.2 World Market Shares (%) of Leading Anti-Obesity Drugs, 2009 

Figure 3.3 Market Shares (%) of Leading Industry Players, 2009

Figure 3.4 Market Shares (%) of Leading Industry Players, 2010

Figure 3.5 Total Anti-Obesity Drug Treatments Market: Revenues ($m), 2009-2021

Figure 4.1 World Xenical Revenues ($m), 2009-2021

Figure 4.2 World Alli Revenues ($m), 2009-2021

Figure 4.3 World Reductil Revenues ($m), 2009-2021

Figure 4.4 World Dinintel Revenues ($m), 2009-2021

Figure 4.5 World Duromine Revenues ($m), 2009-2021

Figure 4.6 Total Other Anti-Obesity Drugs: World Revenues ($m), 2009-2021

Figure 4.7 Top Tier Anti-Obesity Drug Revenues ($m), 2011-2021

Figure 4.8 World Revenues ($m) of Market Leaders in the Anti-Obesity Drug Treatments Market, 2009-2021

Figure 4.9 World Market Shares (%) of Leading Anti-Obesity Drugs, 2015

Figure 4.10 World Market Shares (%) of Leading Anti-Obesity Drugs, 2021

Figure 7.1 US Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.2 UK Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.3 Spanish Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.4 German Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.5 French Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.6 Italian Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.7 Russian Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.8 Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2011-2021 

Figure 7.9 Indian Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.10 Rest of the World Anti-Obesity Drug Market Revenues ($m), 2009-2021

Figure 7.11 World Market Shares (%) for Anti-Obesity Drug Treatments, 2009

Figure 7.12 World Market Shares (%) for Anti-Obesity Drug Treatments, 2015

Figure 7.13 World Market Shares (%) for Anti-Obesity Drug Treatments, 2021

Figure 7.14 Anti-Obesity Drug Treatments: Geographical Market Revenues ($m), 2009-2021

Companies Listed

7TM Pharma 

Abbott Laboratories

Ache Laboratories

Actavis

Alizyme

American Home Products

American Obesity Association

Amylin

Arena Pharmaceuticals

AstraZeneca 

Athersys

Barcelona University

Bayer

Bayer Schering

Biovitrum

Braasch Biotech LLC

Bristol-Myers Squibb

Clinuvel

Compellis

Council for Scientific and Industrial Research

Duke University

Eli Lilly

European Medicines Agency (EMEA/EMA)

Emisphere

EMS

Epix

Eurofarma

Food and Drug Administration (US FDA)

Forbes Medi-Tech

Gate Pharmaceuticals

Genaera

GlaxoSmithKline

Graceway Pharma

GW Pharmaceuticals

Han Wha

Hanmi

Inova Pharma

International Association for the Study of Obesity

Johnson & Johnson

Kalypsys

Kissei

KVK-Tech

Kyorin

Liomont

Louisiana State University

Medley

Menarini

Merck & Co.

National Health Service (NHS)

Neurogen

NeuroSearch

Nintendo

Nisshin Pharma

Nisshin Seifun Group

North American Association for the Study of Obesity

Novartis

Novo Nordisk

Nycomed Pharma

OBEcure

Orexigen

Organisation for Economic Cooperation and Development (OECD)

OSI Pharmaceuticals

Pennington Biomedical Research Institute, Louisiana State University

Pfizer

Phytopharm

Public Citizen

Rimsa Mexico

Roche

Sanofi-Aventis

Shionogi

Sirtris Pharmaceuticals

Solvay

Surface Logix

Taisho

Takeda Pharmaceutical Company

Teva

Transition

TransTech

University of Alberta

URL Pharma

US Department of Health and Human Services

Vernalis

Vivus

World Health Organization (WHO)

Wyeth (now part of Pfizer)

Zydus Cadila

To order this report:

: World Anti-Obesity Drug Market 2011-2021

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds World Biological Drugs Market 2011-2021
2. Reportlinker Adds World Influenza Vaccines Market 2011-2021
3. Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies
4. Reportlinker Adds Enzymes in Drug Manufacturing
5. Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects
6. Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies
7. Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing
8. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
9. Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
10. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
11. Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016   National Community Pharmacists Association ... issued the following statement today in response to the ... the Centers for Medicare & Medicaid Services (CMS) and ... advocates and others: patient advocacy organizations ... reviewing the full CMS analysis. Our initial reaction is ...
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health ... Dwight Howard to bring a one-of-a-kind experience ... . Using cutting-edge technologies such as 360-degree video and ... both virtually, then literally – giving the patients and ... and it was all caught on video . ...
Breaking Medicine Technology:
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... as a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) ... channel partners to offer real-time business intelligence (BI) to their small and medium ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a ... initiating a charity drive that will raise funds earmarked to purchase computers and software ... Elementary School. , “My school is in a low-income area and has more than ...
Breaking Medicine News(10 mins):